# US 2022/0016080 A1 · Compounds that selectively and effectively inhibit hakai-mediated ubiquitination, as anti-cancer drugs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0016080 A1
- Document ID: US20220016080A1
- Status: Published application
- Kind: A1
- Application number: 17/293,884
- Filed: 2019-11-15
- Published: 2022-01-20
- Earliest claimed: 2018-11-15
- Applicants: FundacióN Profesor Novoa Santos
- Inventors: Angélica FIGUEROA CONDE-VALVÍS; Federico GAGO BADENAS; Olala Antía MARTÍNEZ IGLESIAS; Raquel CARBALLO CASTOSA; Álvaro CORTÉS CABRERA; Alba CASAS PAIS
- Web page: https://patentgrep.com/patent/US20220016080A1

## CPC

- A61K 31/41: having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 31/433: Thidiazoles
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/497: containing further heterocyclic rings
- A61K 31/501: not condensed and containing further heterocyclic rings
- A61K 31/5355: Non-condensed oxazines and containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a class of compounds, which includes enantiomers and pharmaceutically acceptable salts thereof, that selectively and effectively inhibit Hakai-mediated ubiquitination, preferably without affecting Hakai protein levels, thereby representing excellent anti-cancer drugs useful in the treatment of a variety of cancers, such as carcinomas, in particular, tumors arising from the epithelial layers of the gastrointestinal track including month (oral cancer), esophagus, stomach, and small and large intestines (such as rectal or colon cancer). It also includes skin cancer, mammary gland (breast cancer), pancreas cancer, lung cancer, head and neck cancer, liver cancer, ovary cancer, cervix cancer, uterus cancer, gallbladder cancer, penile cancer, and urinary bladder cancer (such as renal, prostate or bladder cancer).

## Claims

### Claim 1

A compound of formula (I)
wherein:
A represents a group selected from aryl, heteroaryl and cyclic amides optionally substituted by 1 or 2 groups that are independently selected from:
i) halogen atom, NO2, —CN, —N(Ra)Rb, —ORa, —C(═O)Ra, —C(═O)ORa, —C(═O)N(Ra)Rb, —OC(═O)—Ra, —N(Rc)C(═O)Rb, —NRcSO2Ra, —SO2N(Ra)Rb, —SRa, —S(O)Ra, —S(O)2Ra;
j) linear or branched C1-C6 alkyl, optionally substituted by 1, 2 or 3 halogen atoms;
k) C3-C6 cycloalkyl which optionally contains 1 or 2 heteroatoms selected from O, S and N, and which ring is optionally substituted by C1-C3 alkyl;
l) phenyl or C5-C6 heteroaryl each optionally substituted by halogen atom, cyano group, C1-C3 alkyl or cyclopropyl;
each Ra, Rb and RC independently represents:
i) hydrogen atom,
j) linear or branched C1-C12 alkyl, C3-C6 cycloalkyl and C4-C6 heterocycloalkyl, which are optionally substituted by 1, 2 or 3 substituents selected from a carbonyl group, halogen atom, hydroxy, phenyl, C3-C6 cycloalkyl, linear or branched C1-C6 alkoxy, amino, alkylamino, dialkylamino, linear or branched C1-C6 alkylcarbonyl,
k) phenyl or C5-C6 heteroaryl group, which are optionally substituted by 1, 2 or 3 substituents selected from halogen atom, cyano group, linear or branched C1-C6 alkyl, linear or branched C1-C6 haloalkyl, hydroxy, linear or branched C1-C6 alkoxy, amino, alkylamino, dialkylamino;
l) Ra and Rb form together with the nitrogen atom to which they are attached, a 3- to 8 membered ring which optionally contains a further heteroatom selected from O, N and S, and which ring is optionally substituted by 1, 2 or 3 substituents selected from carbonyl group, linear or branched C1-C6 alkyl, linear or branched C1-C6 haloalkyl, linear or branched C1-C6 alkylcarbonyl;
x and y are integers independently selected from 0 and 1;
R1 represents a group selected from hydrogen, cyclopropyl or linear or branched C1-C6 alkyl, wherein said alkyl is optionally substituted by 1, 2 or 3 halogen atoms;
when y is 0, then 2 or 3 carbon atoms of R1 can form a 5- or 6-membered ring together with the neighboring nitrogen atom and the 2 adjacent carbon atoms of the aromatic ring to which the nitrogen is attached;
each R2 and R3 independently represent a cyclopropyl or linear or branched C1-C6 alkyl;
R2 and R3 can form a 3-or 4-membered spiro ring together with the carbon atom to which they are both attached;
z is an integer selected from 0, 1, 2 or 3;
R4 represents a group selected from —CN, cyclopropyl or linear or branched C1-C6 alkyl, said alkyl is optionally substituted by 1, 2 or 3 halogen atoms; wherein the group R4, if present, replaces the hydrogen atom of one of the groups CH present in the phenyl ring to which R4 is attached;
and pharmaceutically acceptable salts thereof;
for use in the treatment of cancer.

### Claim 2 (depends on 1)

The compound for use according to claim 1, wherein the cancer is a carcinoma.

### Claim 3 (depends on 2)

The compound for use according to claim 2, wherein the cancer is a carcinoma selected from the list consisting of tumors arising from epithelial layers of the gastrointestinal track including month (oral cancer), esophagus, stomach, and small and large intestines (such as rectal or colon cancer), skin cancer, mammary gland (breast cancer), pancreas cancer, lung cancer, head and neck cancer, liver cancer, ovary cancer, cervix cancer, uterus cancer, gallbladder cancer, penile cancer, and urinary bladder cancer (such as renal, prostate or bladder cancer).

### Claim 4 (depends on 1, 2, 3)

The compound for use according to any of claims 1 to 3, wherein each R2 and R3 independently represents a group selected from cyclopropyl or a linear or branched C1-C6 alkyl.

### Claim 5 (depends on 1, 2, 3)

The compound for use according to any of claims 1 to 3, wherein R2 and R3 form a 3-or 4-membered spiro ring together with the carbon atom to which they are both attached.

### Claim 6 (depends on 1, 2, 3)

The compound for use according to any of claims 1 to 3, wherein z is an integer selected from 1, 2 or 3; wherein R4 represents a group selected from —CN, cyclopropyl or a linear or branched C1-C6 alkyl, wherein said alkyl is optionally substituted by 1, 2 or 3 halogen atoms; and wherein group R4 replaces the hydrogen atom of one of the groups CH present in the phenyl ring to which R4 is attached.

### Claim 7 (depends on 1, 2, 3)

The compound for use according to any of claims 1 to 3, wherein one or both of the integers x and y equal 1 and A represents a group selected from aryl, heteroaryl and cyclic amides optionally substituted by 1 or 2 groups that are independently selected from halogen atom, —CN, —N(Ra)Rb, —ORa, —C(═O)Ra, —C(═O)ORa, —C(═O)N(Ra)Rb, —OC(═O)—Ra, —N(Rc)C(═O)Rb, —NRcSO2Ra, —SO2N(Ra)Rb, —SRa, —S(O)Ra, —S(O)2Ra, linear or branched C1-C6 alkyl, wherein said alkyl is optionally substituted by 1, 2 or 3 halogen atoms; C3-C6 cycloalkyl which optionally contains 1 or 2 heteroatoms selected from O, S and N, and which ring is optionally substituted by C1-C3 alkyl; phenyl or C5-C6 heteroaryl each optionally substituted by halogen atom, C1-C3 alkyl or cyclopropyl.

### Claim 8 (depends on 1, 2, 3)

The compound for use according to any of claims 1 to 3, wherein the compound is selected from the list consisting of any of the following compounds:

### Claim 9 (depends on 1, 2, 3)

The compound for use according to any of claims 1 to 3, wherein the compound is 4-(5-((2-(4-nitrophenyl)-2-oxoethyl)thio)-1H-tetrazol-1-yl)benzoic acid.

### Claim 10 (depends on 1, 2, 3)

The compound for use according to any of claims 1 to 3, wherein the compound is selected from the list consisting of any of the following compounds:

### Claim 11 (depends on 1, 2, 3)

The compound for use according to any of claims 1 to 3, wherein the compound is selected from the list consisting of any of the following compounds:

### Claim 12 (depends on 1, 2, 3)

The compound for use according to any of claims 1 to 3, wherein the compound is
wherein R represents a group selected from hydrogen, cyclopropyl or linear or branched C1-C6 alkyl, wherein said alkyl is optionally substituted by 1, 2 or 3 halogen atoms.

### Claim 13 (depends on 1, 2, 3)

The compound for use according to any of claims 1 to 3, wherein the compound is
wherein R is a methyl group.

### Claim 14 (depends on 1, 2, 3)

The compound for use according to any of claims 1 to 3, wherein the compound is selected from the list consisting of any of the following compounds:
